BG107330A - Заместени имидазоли като инхибитори на tafia - Google Patents

Заместени имидазоли като инхибитори на tafia

Info

Publication number
BG107330A
BG107330A BG107330A BG10733002A BG107330A BG 107330 A BG107330 A BG 107330A BG 107330 A BG107330 A BG 107330A BG 10733002 A BG10733002 A BG 10733002A BG 107330 A BG107330 A BG 107330A
Authority
BG
Bulgaria
Prior art keywords
tafia inhibitors
substituted imidazoles
compounds
tafia
inhibitors
Prior art date
Application number
BG107330A
Other languages
English (en)
Inventor
Charlotte ALLERTON
Julian Blagg
Mark Bunnage
John Steele
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020346A external-priority patent/GB0020346D0/en
Priority claimed from GB0027409A external-priority patent/GB0027409D0/en
Priority claimed from GB0029556A external-priority patent/GB0029556D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG107330A publication Critical patent/BG107330A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Изобретението се отнася до съединения с формула. Те са клас от инхибитори на TAFIа и са приложими за лечение на атеросклероза, адхезии, кожни белези,рак, фиброзни заболявания, възпалителни болести итакива, които се благоприятстват от поддържане илиусилване на нивата на брадикинин в организма.
BG107330A 2000-08-17 2002-11-28 Заместени имидазоли като инхибитори на tafia BG107330A (bg)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0020346A GB0020346D0 (en) 2000-08-17 2000-08-17 Pharmaceuticals
GB0027409A GB0027409D0 (en) 2000-11-09 2000-11-09 Pharmaceuticals
GB0029556A GB0029556D0 (en) 2000-12-04 2000-12-04 Pharmaceuticals
PCT/IB2001/001425 WO2002014285A1 (en) 2000-08-17 2001-08-08 Substituted imidazoles as tafia inhibitors

Publications (1)

Publication Number Publication Date
BG107330A true BG107330A (bg) 2003-06-30

Family

ID=27255849

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107330A BG107330A (bg) 2000-08-17 2002-11-28 Заместени имидазоли като инхибитори на tafia

Country Status (38)

Country Link
EP (1) EP1311488B1 (bg)
JP (2) JP4119746B2 (bg)
KR (1) KR20030022412A (bg)
CN (1) CN1443173A (bg)
AP (1) AP1375A (bg)
AR (1) AR035580A1 (bg)
AT (1) ATE447557T1 (bg)
AU (1) AU2001276605A1 (bg)
BG (1) BG107330A (bg)
BR (1) BR0113289A (bg)
CA (1) CA2419633C (bg)
CY (1) CY1109693T1 (bg)
CZ (1) CZ2003388A3 (bg)
DE (1) DE60140368D1 (bg)
DK (1) DK1311488T3 (bg)
DO (1) DOP2001000233A (bg)
EA (1) EA005532B1 (bg)
EE (1) EE200300070A (bg)
ES (1) ES2334101T3 (bg)
HR (1) HRP20030103A2 (bg)
HU (1) HUP0303763A3 (bg)
IL (1) IL153225A0 (bg)
IS (1) IS6638A (bg)
MA (1) MA26940A1 (bg)
MX (1) MXPA03001425A (bg)
NO (1) NO20030706L (bg)
NZ (1) NZ522823A (bg)
OA (1) OA12362A (bg)
PA (1) PA8525401A1 (bg)
PE (1) PE20020352A1 (bg)
PL (1) PL361054A1 (bg)
PT (1) PT1311488E (bg)
SI (1) SI1311488T1 (bg)
SK (1) SK1732003A3 (bg)
SV (1) SV2002000602A (bg)
TN (1) TNSN01126A1 (bg)
UY (1) UY26889A1 (bg)
WO (1) WO2002014285A1 (bg)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
KR20040077775A (ko) * 2002-01-22 2004-09-06 화이자 인코포레이티드 ＴＡＦＩａ 억제제로서의3-(이미다졸릴)-2-알콕시프로피온산
MXPA04005940A (es) 2002-01-22 2004-09-13 Pfizer Acidos 3-(imidazolil)-2-aminopropanoicos.
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
US8512675B2 (en) 2003-04-29 2013-08-20 Mallinckrodt Llc N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
ZA200603165B (en) * 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
DE102005049385A1 (de) * 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
CN101553219B (zh) * 2006-12-06 2013-04-24 塞诺菲-安万特股份有限公司 作为TAFIa抑制剂的脲和磺酰胺衍生物
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
US20110213143A1 (en) * 2008-10-29 2011-09-01 Taisho Pharmaceutical Co., Ltd. Compound having tafia inhibitory activity
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2793523C (en) * 2010-03-18 2015-05-05 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
SI2548871T1 (sl) * 2010-03-18 2017-10-30 Daiichi Sankyo Company, Limited S cikloalkilom substituiran derivat imidazola
PL2716684T3 (pl) * 2011-05-17 2020-01-31 Joint Stock Company "Pharmasyntez" Związki do profilaktyki i leczenia procesu powstawania zrostów
JP5996647B2 (ja) * 2011-07-22 2016-09-21 カンブレックス カルルスクーガ アクチ ボラケットＣａｍｂｒｅｘ Ｋａｒｌｓｋｏｇａ Ａｂ ４−置換イミダゾールの新規な調製プロセス
WO2013039202A1 (ja) * 2011-09-15 2013-03-21 第一三共株式会社 新規アクリル酸誘導体
JP6461113B2 (ja) 2013-06-10 2019-01-30 サノフイＳａｎｏｆｉ ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用
MA52098A (fr) 2015-10-07 2021-01-27 Mitobridge Inc Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20180123038A (ko) 2016-03-29 2018-11-14 다이이찌 산쿄 가부시키가이샤 염증성 장질환 치료제
CA3019014A1 (en) 2016-04-13 2017-10-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN113943255B (zh) * 2020-07-17 2024-08-06 深圳信立泰药业股份有限公司 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163661A (ja) * 1984-09-05 1986-04-01 Microbial Chem Res Found ヒスタジン関連化合物
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
JP4778531B2 (ja) 2011-09-21
IL153225A0 (en) 2003-07-06
ATE447557T1 (de) 2009-11-15
SV2002000602A (es) 2002-10-24
NZ522823A (en) 2004-11-26
SK1732003A3 (en) 2004-08-03
JP2004506044A (ja) 2004-02-26
SI1311488T1 (sl) 2010-01-29
CA2419633C (en) 2011-05-10
PE20020352A1 (es) 2002-05-11
IS6638A (is) 2002-11-28
AP1375A (en) 2005-03-03
OA12362A (en) 2004-04-07
UY26889A1 (es) 2002-03-22
PL361054A1 (en) 2004-09-20
EP1311488A1 (en) 2003-05-21
EA005532B1 (ru) 2005-04-28
MXPA03001425A (es) 2003-06-06
PA8525401A1 (es) 2002-04-25
DE60140368D1 (de) 2009-12-17
EP1311488B1 (en) 2009-11-04
AP2001002250A0 (en) 2001-09-30
HRP20030103A2 (en) 2003-04-30
HUP0303763A3 (en) 2004-06-28
BR0113289A (pt) 2003-06-17
NO20030706L (no) 2003-04-15
CN1443173A (zh) 2003-09-17
CZ2003388A3 (cs) 2004-03-17
ES2334101T3 (es) 2010-03-05
DK1311488T3 (da) 2010-01-04
WO2002014285A1 (en) 2002-02-21
EE200300070A (et) 2005-02-15
HUP0303763A2 (hu) 2004-04-28
AU2001276605A1 (en) 2002-02-25
DOP2001000233A (es) 2002-05-15
PT1311488E (pt) 2009-12-30
CA2419633A1 (en) 2002-02-21
JP4119746B2 (ja) 2008-07-16
TNSN01126A1 (fr) 2005-11-10
JP2008169224A (ja) 2008-07-24
KR20030022412A (ko) 2003-03-15
AR035580A1 (es) 2004-06-16
EA200201239A1 (ru) 2003-08-28
NO20030706D0 (no) 2003-02-14
MA26940A1 (fr) 2004-12-20
CY1109693T1 (el) 2014-08-13

Similar Documents

Publication Publication Date Title
BG107330A (bg) Заместени имидазоли като инхибитори на tafia
BG105800A (bg) Бензохетероцикли и приложението им като инхибитори на мек
BG106585A (bg) Киназни инхибитори като лекарствени средства
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
EG25017A (en) N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobials.
YU21401A (sh) Tetrahidropiridoetri
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1171428A4 (en) FAB I INHIBITORS
ATE332302T1 (de) Alkylierte imidazopyridinderivate
HK1056175A1 (en) Prodrugs of imidazopyridine derivatives
MY128164A (en) Compounds
NO20015892D0 (no) Inhibitorer av metallproteinaser
TW200509921A (en) Alkaline salts
ATE269313T1 (de) Tryptase-inhibitoren
HK1049146A1 (en) Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23.
PT1244614E (pt) Inibidores de triptase
AU2003259159A1 (en) N-aryl-2-oxazolidinones and their derivatives
MXPA02008014A (es) Composiciones inhibidoras de tumores de 1-nitroacridina.
DE60216920D1 (en) Tryptase-inhibitoren
DE60220504D1 (en) Tryptasehemmer
DE60120398D1 (de) Imidazopyridin-8-one
UA33865A (uk) Дикалієва сіль n-сукцин - dl-триптофану, що має антиангінальну та антигіпоксантну дію